Solara Active Pharma Sciences Limited has informed the exchange regarding the Press Release dated July 23, 2026, titled - Solara reports Strong Q1''27 Base business performance with Continued ....
Press Release - Q1FY27
- Overall revenue 3.84bn INR +20% y-y; EBITDA 635mn INR +10% y-y; PAT 163mn INR +55% y-y
- Base business revenue 3.08bn INR +24% y-y; EBITDA 722mn INR +8% y-y despite West Asia input cost pressures
- Ibuprofen business revenue 765mn INR +7% y-y; EBITDA loss narrowed to 87mn INR
- Net debt reduced by 1.35bn INR in Q1, net debt to EBITDA ratio ~1.9 (annualized)
- Management evaluating strategic options for Ibuprofen business, decision expected by Q2FY27
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 SOLARA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add SOLARA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Solara Active Pharma Sciences Limited
Important.
The summary above is generated automatically from Solara Active Pharma Sciences Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.